Verstovsek S et al. Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: Survival advantage of ruxolitinib therapy. Proc ASH 2011;Abstract 793.

Dr Verstovsek is Associate Professor, Chief of the Section of Myeloproliferative Neoplasms and Director of the Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center in Houston, Texas.